This week on “The Top Line,” we break down the biggest stories out of JPM, from J&J’s blockbuster acquisition of ...
As the year gets underway, analysts and biotech executives highlight cell therapy’s pivot from oncology to autoimmune ...
11d
Plus: A stomach flu vaccine, the health impacts of California’s wildfires, lots of nine-figure deals for healthcare startups ...
Subscribe to The Economic Times Prime and read the ET ePaper online.
Medicines Discovery Catapult (MDC), the UK government-backed life sciences service dedicated to driving productivity and ...
California-based immunology start-up Ouro Medicines, which is developing immune reset therapeutics for people living with ...
Even before that deal, AbbVie had been showing an interest in the modality, with then-CEO Richard Gonzalez telling analysts ...
Drugmaker GSK has agreed to pay up to 1.15 billion US dollars (£950 million) for a US-based biopharmaceutical company which is developing rare cancer therapies. GSK said the acquisition of IDRx w ...
Drugmaker GSK has agreed to pay up to 1.15 billion US dollars (£950 million) for a US-based biopharmaceutical company which is developing rare cancer therapies. GSK said the acquisition of IDRx will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback